Gene Expression Profiling for Melanoma

Effective: July 1, 2020

Next Review: April 2021
Last Review: May 2020

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Gene expression assays have been created to aid risk stratification in patients with melanoma or pigmented lesions suspected of being melanoma.

MEDICAL POLICY CRITERIA

I. The DecisionDx-UM™ gene expression assay may be considered medically necessary in patients with primary, localized uveal melanoma.

II. The DecisionDx-UM™ gene expression assay is considered investigational for patients that do not meet criterion I.

III. All other gene expression assays for melanoma are considered investigational, including but not limited to DecisionDX-Melanoma™, Pigmented Lesion Assay, and myPath Melanoma™.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

LIST OF INFORMATION NEEDED FOR REVIEW

It is critical that the list of information below is submitted for review to determine if the policy criteria are met. If any of these items are not submitted, it could impact our review and decision.
outcomes.

- Name of the genetic test(s) or panel test
- Name of the performing laboratory and/or genetic testing organization (more than one may be listed)
- The exact gene(s) and/or mutations being tested
- Relevant billing codes
- Brief description of how the genetic test results will guide clinical decisions that would not otherwise be made in the absence testing
- Medical records related to this genetic test
  - History and physical exam
  - Conventional testing and outcomes
  - Conservative treatment provided, if any

CROSS REFERENCES
1. [Genetic Testing for Cutaneous Malignant Melanoma](#), Genetic Testing, Policy No. 08
2. [Genetic and Molecular Diagnostic Testing](#), Genetic Testing, Policy No. 20
3. [Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer](#), Genetic Testing, Policy No. 42

BACKGROUND

CUTANEOUS MELANOMA

Cutaneous melanoma represents less than 5% of skin malignancies but results in the most skin cancer deaths. The incidence of cutaneous melanoma continues to increase, and it is currently the sixth most common cancer in the United States. Standard treatment options for stage 1 and 2 melanoma is excision with or without sentinel lymph node examination. Current risk factors to predict localized tumor aggression include Breslow tumor thickness, tumor ulceration, and mitotic rate of the tumor cells. Regional lymph node involvement, the likelihood of which increases with increasing tumor thickness, significantly negatively impacts the rate of survival.

UVEAL MELANOMA

Uveal melanoma (UM), also referred to as ocular or choroidal melanoma, is the most common, but rare, primary ocular malignancy in adults and shows a strong tendency for metastases to the liver. Approximately four million cases of UM occur each year.[1] Even with successful treatment of the primary tumor, up to 50% of individuals subsequently develop systemic metastases, with liver involvement in up to 90% of these individuals. Despite aggressive systemic treatments, metastatic liver disease remains the most common cause of tumor-related mortality in choroidal malignant melanoma, with a median survival time of two to seven months and a one-year survival rate of less than 10%. The primary clinical issue in the management of UM is accurately predicting risk of metastasis.

Identifying patients at high risk for metastatic disease might assist in selecting patients for adjuvant treatment and more intensive surveillance for metastatic disease, if such changes lead to improved outcomes. The optimal method and interval for surveillance are not well-defined, and it has not been established in prospective trials whether surveillance identifies metastatic disease earlier. Potential methods for metastases include magnetic resonance imaging, ultrasound, liver function testing, and positron emission tomography scans.
COMMERCIALY AVAILABLE TESTING

The DermTech Pigmented Lesion Assay (PLA) test measures expression of six genes (PRAME, LINC00518, CMIP, B2M, ACTB, PPIA). The test is performed on skin samples of lesions at least 5 mm in diameter obtained via noninvasive, proprietary adhesive patch biopsies of a stratum corneum specimen. The test does not work on the palms of hands, soles of feet, nails, or mucous membranes and should not be used on bleeding or ulcerated lesions. The PLA test report includes two results. The first is the PLA MAGE (Melanoma Associated Gene Expression), which indicates low risk (neither PRAME nor LINC00518 expression was detected), moderate risk (expression of either PRAME or LINC00518 was detected), or high risk (expression of both PRAME and LINC00518 was detected). The second result is as an algorithmic PLA score that ranges from 0 to 100, with higher scores indicating higher suspicion of malignant disease. It is not clear whether the PLA test is meant to be used as a replacement, triage, or add-on test with respect to dermoscopy.

The Myriad myPath test measures expression of 23 genes. Fourteen genes are involved in melanoma pathogenesis and are grouped into three components related to cell differentiation, cell signaling, and the immune response, and nine housekeeper genes are also included. The test is performed on five standard tissue sections from an existing formalin-fixed, paraffin-embedded biopsy specimen, and the test report includes an algorithmic myPath score ranging from -16.7 to 11.1, with higher, positive scores indicating higher suspicion of malignant disease. The myPath report classifies these scores: -16.7 to -2.1 are “benign”; -2.0 to -0.1 are “indeterminate”; and 0.0 to +11.1 are “malignant”.

The DecisionDx-Melanoma™ is a gene expression profile test that is a signature of 31 genes, 28 discriminating genes, and three control genes. The test is used to measure risk of metastasis in patients with stage 1 and 2 cutaneous melanoma and classifies tumors into two groups of risk of metastasis, high or low (Class 1 and 2, respectively). The test purports to give an independent prediction of risk of tumor metastatic risk, independent of currently used metrics of risk assessment (e.g., Breslow’s thickness, ulceration status, and mitotic rate; American Joint Committee on Cancer stage, sentinel lymph node biopsy status), so that patients with high-risk stage 1 or 2 disease can possibly undergo more aggressive surveillance treatment than they would have otherwise received.

The DecisionDx-UM™ test (Castle Biosciences Inc.) is a commercially marketed gene expression profiling test intended for use in assessing metastatic risk in individuals with this condition. It consists of a 15-gene polymerase chain reaction (PCR)-based assay that stratifies individuals with UM into two classes based on the molecular signature of tumor tissue. Uveal melanomas cluster into two molecular groups based on their gene expression profile. Tumors with the Class 1 signature rarely metastasize, whereas those with the Class 2 signature metastasize at a high rate. Class 1 tumors have been further distinguished into Class 1a (lowest metastatic risk) and Class 1b (moderate long-term metastatic risk).

According to Castle Biosciences Inc., the DecisionDx-UM™ test results are used for the following:

- To initiate referral to a medical oncologist for treatment planning which may include adjuvant treatment.
- To develop specific monitoring or surveillance plans:
More frequent monitoring with advanced imaging procedures may be recommended for those individuals identified as having a high risk of developing metastasis.

For individuals at a low risk of developing metastasis, a less intensive surveillance plan may balance the risks of radiation exposure associated with less frequent imaging.

- To improve life-planning.

REGULATORY STATUS

The DecisionDx tests are performed in a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory and do not require U.S. Food and Drug Administration (FDA) clearance.

Note: Microarray-based gene expression analysis of prostate cancer and breast cancer are addressed in separate medical policies (see Cross References).

EVIDENCE SUMMARY

Human Genome Variation Society (HGVS) nomenclature\(^2\) is used to describe variants found in DNA and serves as an international standard. It is being implemented for genetic testing medical evidence review updates starting in 2017. According to this nomenclature, the term “variant” is used to describe a change in a DNA or protein sequence, replacing previously-used terms, such as “mutation.” Pathogenic variants are variants associated with disease, while benign variants are not. The majority of genetic changes have unknown effects on human health, and these are referred to as variants of uncertain significance.

Validation of the clinical use of any genetic test focuses on three main principles:

1. **Analytic validity**, which refers to the technical accuracy of the test in detecting a variant that is present or in excluding a variant that is absent;
2. **Clinical validity**, which refers to the diagnostic performance of the test (sensitivity, specificity, positive and negative predictive values) in detecting clinical disease; and
3. **Clinical utility**, i.e., how the results of the diagnostic test will be used to change management of the patient and whether these changes in management lead to clinically important improvements in health outcomes.

Review of the literature focused on identifying evidence related to clinical validity and clinical utility, particularly whether the tests can be used to improve treatment planning compared with the standard of care, and whether their use results in improved health outcomes.

EVALUATION OF SUSPICIOUS PIGMENTED LESIONS

Primary care providers evaluate suspicious pigmented lesions to determine who should be referred to dermatology. Factors considered include both a patient’s risk for melanoma as well as a visual examination of the lesion. The visual examination assesses whether the lesion has features suggestive of melanoma. Criteria for features suggestive of melanoma have been developed. One checklist is the ABCDE checklist:\(^3\)

- Asymmetry;
- Border irregularities;
- Color variegation;
- Diameter ≥6 mm;
Another criterion commonly used is the “ugly duckling” sign. An ugly duckling is a nevus that is obviously different from others in a given patient. Primary care providers generally have a low threshold for referral to dermatology. Melanoma is difficult to diagnose based on visual examination, and the criterion standard for diagnosis is histopathology. There is a low threshold for excisional biopsy of suspicious lesions for histopathologic examination due to the procedure’s ease and low risk as well as the high probability of missing melanoma. However, the yield of biopsy is fairly low. The number of biopsies performed to yield one melanoma diagnosis has been estimated to be about 15 for U.S. dermatologists. Therefore a test that could accurately identify those lesions not needing a biopsy (i.e., a rule-out test for biopsy) could be clinically useful. The purpose of gene expression profiling (GEP) in patients who have suspicious pigmented lesions being considered for biopsy is to inform a decision about whether to biopsy.

Clinical Validity

Studies were excluded from the evaluation of the clinical validity of the PLA test because they reported results of the development cohort, they did not use the marketed version of the test, did not include the reference standard test on PLA-negative patients, did not adequately describe the patient characteristics, or did not adequately describe patient selection criteria.

The validation cohort from the Gerami (2017) publication was included. This was a retrospective study that included lesions that were selected by dermatologists experienced in pigmented lesion management from 28 sites in the United States, Europe, and Australia; therefore, the samples were likely not consecutive or random. Information regarding the previous testing was not provided. The flow of potential and included samples was not clear, and neither was whether the samples were all independent or if multiple samples from the same patient were included. Diagnosis of melanoma was based on consensus among a primary reader and three expert dermatopathologists. The report did not state whether the histopathologic diagnosis was blinded to the results of the PLA test but did state the diagnosis was “routinely” assessed. Interpretation of the PLA result does not depend on a reader, so it is blinded to histopathologic results. In 11% of cases originally selected, a consensus diagnosis was not reached, and these samples were not included in the training or validation cohorts. Dates of data collection were not reported. Sex and anatomic location of biopsy were reported, but other clinical characteristics (e.g., risk factors for melanoma, presenting symptoms) were not. The study training cohort included 157 samples with 80 melanomas and 77 nonmelanomas. The study validation cohort included 398 samples with 87 melanomas (22%) and 311 non-melanomas. The sensitivity and specificity of the test in this group was 91% (95% confidence interval [CI] 83% to 96%) and 69% (95% CI 64% to 74%), respectively, yielding a positive predictive value (PPV) of 45% (95% CI 38% to 53%) and a negative predictive value (NPV) of 96% (95% CI 93% to 98%).

Clinical Utility

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials. No direct evidence of clinical utility was identified.
A decision-impact study by Ferris (2017) assessed the potential impact of PLA on physicians' biopsy decisions in patients.[9] Forty-five dermatologists evaluated 60 clinical and dermoscopic images of atypical pigmented lesions (8 melanoma, 52 nonmelanoma). In the first round, dermatologists did not have PLA test results, and in the second round, dermatologists had access to PLA test results with the order of cases being scrambled. The dermatologists were asked whether the lesions should be biopsied after each round. Therefore, the corresponding number of biopsy decisions should be 45×60×2=5,400. Data were collected in 2014 and 2015. Results were reported for 4,680 decisions with no description of the disposition of the remaining decisions. Of the 4,680 reported decisions, 750 correct biopsy decisions were made without PLA results while 1,331 were made with PLA results and 1,590 incorrect biopsy decisions were made without PLA results while 1,009 incorrect biopsy decisions were made with PLA results.

GEP FOR DIAGNOSING LESIONS WITH INDETERMINATE HISTOPATHOLOGY

The purpose of GEP testing in patients whose melanocytic lesion is indeterminate after histopathology is to aid in the diagnosis of melanoma and decisions regarding treatment and surveillance. In cases of indeterminate histopathology, long-term follow-up is needed to determine evaluate the clinical outcome, specifically metastasis.

Development of the myPath test was described by Clarke (2015).[11] The myPath test is meant to be used as an add-on test to standard histopathology. Studies have evaluated the performance characteristics of the test when histopathology is used as the reference standard,[11-13] but are not the focus of this evidence review given that the test's potential usefulness is in evaluation of indeterminate lesions.

Studies were excluded from the evaluation of the clinical validity of the myPath test because authors did not use the specified reference standard of long-term (at least five years) follow-up[11-16] and/or did not adequately describe patient characteristics.

The clinical validity study by Ko (2017) met selection criteria.[17] For this study, archived melanocytic neoplasms were submitted for myPath testing from university clinics in the United States and United Kingdom with additional samples acquired from Aavden BioSciences. Stage 1, 2, and 3 primary cutaneous melanomas that produced distant metastases subsequent to the diagnosis and benign lesions with clinical follow-up and no evidence of recurrence of metastases were included. For benign samples, a disease-free time of at least five years was recommended. Information on the previous testing was not provided. It is not clear if any of the samples originally had indeterminate histopathology results. Dates of data collection were not reported. Sex, age, Breslow depth, and anatomic location were described; presenting symptoms were not reported. A total of 293 samples were submitted; of these 53 did not meet inclusion criteria and 58 (24% of those tested) failed to produce a valid test score. An additional seven samples with indeterminate results were excluded from the calculations of performance characteristics. Of the remaining 175 samples, 54 were diagnosed as melanoma with metastases. The sensitivity and specificity of the test in this group was 94% (95% CI 87% to 98%) and 96% (95% CI 89% to 99%), respectively, with a PPV of 97% (95% CI 91% to 99%) and an NPV of 93% (95% CI 85% to 97%). A limitation of the study is that it was not limited to lesions that were indeterminate following histopathology. In addition, the samples were not consecutive or random, and it is unclear how much time elapsed between the biopsy and the myPath test.

Clinical Utility
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials. No direct evidence of clinical utility was identified.

Two decision-impact studies assessed the potential impact of myPath on physicians’ treatment decisions in patients with diagnostically challenging lesions.[18,19] Given the lack of established clinical validity and no reported long-term health outcomes, it is not known whether any treatment changes were clinically appropriate.

CUTANEOUS MELANOMA

Many treatments and surveillance decisions are determined by a patient’s prognostic stage group based the American Joint Committee on Cancer tumor, node, metastasis staging system. The prognostic groups are as follows: stage 1, T1a through T2a primary melanomas without evidence of regional or distant metastases; stage 2, T2b through T4b primary melanomas without evidence of lymphatic disease or distant metastases; stage 3: pathologically documented involvement of regional lymph nodes or in transit or satellite metastases (N1 to N3); stage 4: distant metastases. Patients may also undergo sentinel lymph node biopsy to gain more definitive information about the status of the regional nodes. Wide local excision is the definitive surgical treatment of melanoma. Following surgery, patients with American Joint Committee on Cancer stage 1 or 2 (node-negative) melanoma do not generally receive adjuvant therapy. Patients with higher risk melanoma receive adjuvant immunotherapy or targeted therapy. Patients with stage I and IIA disease should undergo an annual routine physical and dermatologic examination. These patients typically do not receive surveillance imaging. Patients with stage 2B – stage 3 melanoma may be managed with more frequent follow-up and imaging surveillance following therapy. However, follow-up strategies and intervals are not based on rigorous data, and opinions vary regarding appropriate strategies.

The purpose of GEP in patients with melanoma is to identify low and high-risk patients classified as stage 1 or 2 according to the American Joint Committee on Cancer (AJCC) criteria. Current guidelines do not recommend adjuvant therapy or imaging surveillance for AJCC stage 1 or 2 patients following surgery. Patients initially staged as 1 or 2 who have positive lymph nodes following sentinel lymph node biopsy (SLNB) are then eligible to be treated with adjuvant therapy as stage 3 patients.

Clinical Validity

Several papers were excluded from the evaluation of clinical validity. Hsueh (2017) and Podlipnik (2019) were excluded from the evaluation of the clinical validity of the DecisionDx test because they did not report five-year outcomes.[20,21] Samples used in Gerami (2015)[22] and Ferris (2017)[23] appear to overlap with the samples from Gerami (2015)[24] and each other and will not be considered independent validation studies for inclusion in the table. They are described briefly following the clinical validity tables. Samples used in both papers by Gastman (2019) are stated to overlap previous validation studies.[25,26] Vetto (2019) included a retrospective cohort that was used to develop the model and is thus not eligible for inclusion, as well a prospective cohort with some overlapping samples and without report of five-year outcomes.[27] A publication by Marks (2019) describes development of a cutpoint.[28]

Four independent clinical validity studies meeting eligibility criteria have been conducted. Characteristics and results are summarized in Tables 1 and 2 and briefly in the paragraphs.
that follow.

**Table 1. Clinical Validity Study Characteristics of the DecisionDx Test for Diagnosing Melanoma**

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Population</th>
<th>Design</th>
<th>Outcome Measure</th>
<th>Threshold for Positive Test</th>
<th>Timing</th>
<th>Assessor Blinding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerami (2015)²⁴</td>
<td>Adults Stage I-IV cutaneous melanoma (87% stage I/II) At least 5 y of FU</td>
<td>Retrospective Not consecutive</td>
<td>5-y RFS</td>
<td>Class 2 is high-risk Risk</td>
<td>Patient diagnosed between 1998 and 2009</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>(median, 7.0 y)</td>
<td>or randomly selected</td>
<td></td>
<td>threshold not provided</td>
<td>Timing of DecisionDx not described</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Median Breslow thickness, 0.8 mm (nonmetastasis) and 3.99 mm (metastasis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SLN positivity NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zager (2018)²⁹</td>
<td>Stage I-III cutaneous melanoma (68% stage I/II) At least 5 y of FU (median, 7.5 y)</td>
<td>Retrospective Not consecutive</td>
<td>5-y RFS</td>
<td>Class 2 = high risk Class 1</td>
<td>Patients diagnosed between 2000 and 2014</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Median Breslow thickness, 1.2 mm 30% SLN positive</td>
<td>or randomly selected</td>
<td></td>
<td>probability score 0.49</td>
<td>Timing of DecisionDx not described</td>
<td></td>
</tr>
<tr>
<td>Greenhaw (2018)³⁰</td>
<td>Patients who were treated for primary invasive CM of any Breslow depth within the last 5 years and had had GEP testing (86% stage I, 14% stage II)</td>
<td>Retrospective Consecutive</td>
<td>5-y MFS</td>
<td>Commercial test cutoffs</td>
<td>Institution offered DecisionDx testing to newly diagnosed and those treated within the previous five years</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Mean follow-up of 23 months; only 20 patients had 5-year follow-up</td>
<td></td>
<td></td>
<td>used</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Table 2. Clinical Validity Study Results of the DecisionDx Test for Diagnosing Melanoma**

<table>
<thead>
<tr>
<th>Study</th>
<th>Initial / Final N</th>
<th>Excluded Samples</th>
<th>Sensitivity, % (95% CI)</th>
<th>Specificity, % (95% CI)</th>
<th>PPV, % (95% CI)</th>
<th>NPV, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerami (2015)[24]</td>
<td>Unclear / 104</td>
<td>Samples excluded if melanoma dx not confirmed, dissectible area not acceptable</td>
<td>89 (73 to 97)(^a)</td>
<td>83 (72 to 91)(^a)</td>
<td>72 (56 to 85)(^a)</td>
<td>93 (84 to 98)(^a)</td>
</tr>
<tr>
<td>Overall</td>
<td>Unclear / 78</td>
<td></td>
<td>86 (64 to 97)(^a)</td>
<td>84 (72 to 93)(^a)</td>
<td>67 (46 to 83)(^a)</td>
<td>94 (84 to 99)(^a)</td>
</tr>
<tr>
<td>Zager (2018)[29]</td>
<td>Overall</td>
<td>Did not meet analytic quality control thresholds</td>
<td>70 (62 to 78)</td>
<td>71 (67 to 76)</td>
<td>48 (41 to 55)</td>
<td>87 (82 to 90)</td>
</tr>
<tr>
<td></td>
<td>Unclear / 264</td>
<td></td>
<td>35 (14 to 62)(^a)</td>
<td>87 (82 to 91)(^a)</td>
<td>15 (6 to 31)(^a)</td>
<td>95 (91 to 98)(^a)</td>
</tr>
<tr>
<td></td>
<td>Unclear / 93</td>
<td></td>
<td>77 (61 to 89)(^a)</td>
<td>43 (29 to 57)(^a)</td>
<td>49 (36 to 62)(^a)</td>
<td>72 (53 to 86)(^a)</td>
</tr>
<tr>
<td>Greenhaw (2018)[30]</td>
<td>256 / 256</td>
<td>None excluded but only 20 had 5-year follow-up</td>
<td>77 (46 to 94)</td>
<td>87 (82 to 91)</td>
<td>24 (13 to 40)</td>
<td>99 (96 to 100)</td>
</tr>
</tbody>
</table>

FU: follow-up; RFS: recurrence-free survival; MFS: metastasis-free survival; GEP: gene expression profiling; CM: cutaneous melanoma; SLN: sentinel lymph node; SNB: sentinel node biopsy

---

**Note:**

- \(^a\) Indicates that the 95% CI is not provided.
<table>
<thead>
<tr>
<th>Study</th>
<th>Initial / Final N</th>
<th>Excluded Samples</th>
<th>Sensitivity, % (95% CI)</th>
<th>Specificity, % (95% CI)</th>
<th>PPV, % (95% CI)</th>
<th>NPV, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keller (2019)[31]</td>
<td>159 / 174</td>
<td>15 patients had insufficient tumor for GEP testing</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

AJCC: American Joint Committee on Cancer; Dx: diagnosis; NPV: negative predictive value; NR: not reported; PPV: positive predictive value; RFS: recurrence-free survival; MFS: metastasis-free survival

a Confidence intervals not provided in the report; calculated from data provided.

The validation cohort in Gerami (2015) included patients with stage 0, 1, 2, 3, or 4 disease from six U.S. centers (n=104).[24] A complete disposition of samples received from the institutions and those included in the analysis was not provided. For 78 patients in the validation cohort with AJCC stage 1 or 2 cutaneous melanoma who had either a metastatic event or had more than five years of follow-up without metastasis, five-year disease-free survival was 98% (CIs not reported) for DecisionDx class 1 patients and 37% for DecisionDx class 2 patients. The PPV and NPV were 67% and 94%, respectively. CIs for performance characteristics were calculated in Table 2 based on data provided.

Zager (2018) reported results of a second clinical validity study including AJCC stage 1, 2, or 3 primary melanoma tumors from 16 U.S. sites.[29] The samples were independent of the other validation studies. Of the 601 cases submitted from the institutions, 523 were included in the analysis (357 stage 1 and 2). The excluded samples did not meet pre- and post-analytic quality control thresholds. SLNB status was untested in 36% of the patients, negative in 34%, and positive in 30%. The report did not describe any adjuvant therapy that the patients received. Overall, 42 (13%) recurrence events occurred in DecisionDx class 1 patients and 100 (48%) recurrence events occurred in DecisionDx class 2 patients. The five-year RFS estimated by Kaplan-Meier was 88% (95% CI 85% to 92%) in class 1 and 52% (95% CI, 46% to 60%) in class 2. The reported sensitivity and specificity were 70% (95% CI 62% to 78%) and 71% (95% CI 67% to 76%), respectively, with a PPV of 48% (95% CI 41% to 55%) and a NPV of 87% (95% CI 82% to 90%). For comparison, the performance characteristics for five-year RFS for sentinel lymph node status among those with SLNB were: sensitivity 66% (95% CI 57% to 74%); specificity 65% (95% CI 58% to 71%); PPV 52% (95% CI 44% to 60%); and NPV 76% (95% CI 69% to 82%). Estimates stratified by AJCC stage I or II are shown in Table 2. If DecisionDx were used as a triage test such that only class 2 received SLNB, then 159 class 1 patients would not have undergone SLNB. Of the 159 patients in class 1, 56 were SLNB-positive and were therefore eligible for adjuvant therapy. It is not clear if the SLNB-positive patients in this study received adjuvant therapy. Of the 56 patients who were DecisionDx class 1 and SLNB-positive, 22 recurrence events occurred by five years.

Greenhaw (2018) reported results of an independent study of the DecisionDx test using their institution’s melanoma registry and including patients who had been treated for cutaneous melanoma within the last five years and undergone DecisionDx testing.[30] Study characteristics and results were reported in the preceding Tables 1 and 2. Two-hundred fifty-six patients were tested; 84% were categorized as DecisionDx class 1 (low-risk) and 16% were DecisionDx class 2 (high-risk). Of these, 219 (86%) tumors were AJCC stage I and 37 (14%) were AJCC stage II. None of the 18 stage 1/class 2 tumors metastasized but 1 (0.5%) of 201 stage 1/class 1 tumors metastasized. Ten (42%) of the stage 2/class 2 tumors metastasized and 2 (15%) of the 13 stage 2/class 1 tumors metastasized.
Keller (2019) reported results of a validity study including 159 patients (ages 26 to 88) diagnosed with melanoma between 2013 and 2015 who underwent SNB and concurrent GEP testing. Study characteristics and results were reported in the preceding Tables 1 and 2. There were 117 patients classified as class 1 (91 subclass 1A and 26 subclass 1B) and 42 classified as Class 2 (12 subclass 2A and 30 subclass 2B); and 78% of the tumors were AJCC stage 1, 13% were stage 2, and 9% were stage 3. Five-year RFS was reported only in a figure and sample sizes at year five and precision estimates were not included. There were six recurrent events (n=117) in class 1 patients by three years (three-year RFS 97%, 95% CI 93% to 100%). There were 23 recurrent events (n=42) in class 2 patients (three-year RFS 47%, 95% CI 34% to 65%). GEP class was significantly associated with RFS in multivariate analysis controlling for age, Breslow thickness, ulceration and SNB results.

In a subsequent analysis of patients with melanoma who had undergone SLNB, Gerami (2015) compared the prognostic accuracy of gene expression profiling (GEP) and biopsy. Patients who had undergone SLNB appear to overlap with patients in Gerami (2015), discussed previously. Most (73%) patients had a negative SLNB, and 27% had a positive SLNB. DecisionDx-Melanoma classified 76 (35%) tumors as low-risk (class 1) and 141 (65%) tumors as high-risk (class 2). Within the group of SLNB-negative patients, the five-year OS rate was 91% in class 1 patients and 55% in class 2 patients. Within the group of SLNB-positive patients, the five-year OS rate was 77% in class 1 patients and 57% in class 2 patients.

Ferris (2017) compared the accuracy of DecisionDx-Melanoma with the web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool. The study included 205 patients who appear to overlap with the patients in the second Gerami (2015) study described above. AJCC-predicted five-year survival for each patient was categorized into low and high-risk based on both a 68% predicted five-year survival and a 79% predicted five-year survival. The 68% and 79% cutpoints were reported to correspond to five-year survival in patients with stage 2A and 2B, respectively, although it is unclear whether those cutpoints were prespecified, whether they were based on internal or external estimates of risk, or whether they are commonly used in practice. The prognostic sensitivity and specificity for death (median follow-up of seven years) of the Decision-Dx Melanoma were 78% and 69%, respectively (CIs not reported). The sensitivity and specificity for the AJCC calculator with the 79% cutpoint were 60% and 74%, respectively. The combination of the DecisionDx-Melanoma and AJCC tools had a sensitivity of 82% and specificity of 62%.

**Clinical Utility**

Four decision-impact studies have been published reporting on the impact of DecisionDx on physicians’ management decisions. Given the lack of established clinical validity and no reported long-term outcomes of the test used to select patients for active surveillance, it is not known whether any management changes were clinically appropriate.

For the proposed use of the test as a triage for SLNB (to identify patients who can avoid SLNB), performance characteristics are not well-characterized. For the proposed use of the test as a replacement for SLNB (identify patients who are AJCC stage 1 or 2 who should receive adjuvant therapy), performance characteristics are also not well-characterized. In addition, an evidence-based management pathway would be needed to support the chain of evidence. The existing RCTs demonstrating that adjuvant therapy reduces recurrence included node-positive patients.
For the proposed use of the test to identify patients who are AJCC stage 1 or 2 who should receive enhanced surveillance, there is also a lack of evidence that imaging surveillance or increased frequency of surveillance improves outcomes in stage 1 and 2 patients. The National Comprehensive Cancer Network guidelines state that imaging surveillance is not recommended for stage 1-2A and can be ‘considered’ for 2B-4, but that there is an absence of meaningful data on the association of rigorous routine surveillance imaging with improved long-term outcome for stage 2B-2C and the recommendations regarding consideration of imaging surveillance remain controversial. While earlier detection of recurrence is thought to be beneficial because lower tumor burden and younger age are associated with improved treatment response and survival, this has not been proven and RCTs are needed to assess whether enhanced surveillance improves survival. The optimal frequency and duration of follow-up surveillance are not standardized and how the surveillance would be altered for DecisionDx class 2 patients has not be defined.

No evidence was identified that demonstrated that adjuvant therapy or increased surveillance improves net health outcomes in AJCC stage 1 or 2 patients who are DecisionDx class 2.

Uveal Melanoma

Clinical Validity

Augsburger (2015) reported on the correlation between GEP classifications when samples from two sites from the same tumor were tested.[36] This prospective, single-center study enrolled 80 patients who had uveal melanoma resection. Tumor samples were taken from two different sites and GEP testing was performed independently on both samples. The primary measure reported was the rate of discordance between the two samples on GEP Class. Nine (11.3%) cases were definitely discordant (95% confidence interval [CI] 9.0% to 13.6%), and 13 (16.3%) cases were definitely or possibly discordant (95% CI 13.0% to 19.6%). Thus, the heterogeneity of tumor and limitations to sampling may explain cases of misclassification where GEP results do not accurately predict prognosis.

Onken (2010) revalidated the GEP assay when it was migrated from a microarray platform to a polymerase chain reaction–based 15-gene assay comprised of 12 discriminating genes and three endogenous control genes from previously published data sets collected from the same group.[37,38] Technical performance of the assay was assessed in 609 tumor samples, including 553 fine needle aspiration biopsies and 56 enucleation specimens from the authors' laboratory (n=188) and 11 collaborating sites (n=421). According to the study protocol, sample failure rate due to incorrect specimen handling was low, occurring in 32 of 609 (5.3%) of samples (p<0.0001). Preliminary data suggested the potential for increased sensitivity of gene expression profiling compared with cytologic diagnosis, as the assay failed in only one of 51 (2%) of samples with insufficient material for cytological diagnosis; however, point estimates of overall test accuracy (e.g., sensitivity, specificity, or both) were not provided. In a subset of 172 individuals with UM, the relationship between tumor class and metastasis was studied with available clinical data and a median follow-up time of 16 months. Within this group, the assay was reported to correctly identify individuals who went on to develop metastatic disease. Kaplan-Meier analysis showed approximately 24% Class 2 individuals with UM surviving at 48 months and close to 100% survival in the Class 1 group, although more specific data was not provided. This study evaluated primarily fine needle aspiration biopsy specimens (553 of 609, or 90.8%) rather than enucleation specimens; however, the data reported on the relationship between tumor class and metastasis are limited, and median follow-up time was reported as a relatively short duration (16 months).
In a prospective, multicenter study by Onken (2012), the prognostic performance of the 15-gene GEP assay was evaluated in 459 patients with posterior UM from 12 independent centers.[39] Tumors were classified by GEP as Class 1 or Class 2. The first 260 samples were also analyzed for chromosome 3 status using a single nucleotide polymorphism assay. Net reclassification improvement analysis was performed to compare the prognostic accuracy of GEP with the 7th edition clinical Tumor-Node-Metastasis (TNM) classification and chromosome 3 status. Patients were managed for their primary tumor and monitored for metastasis. The GEP assay successfully classified 446 of 459 cases (97.2%). Metastasis was detected in three Class 1 cases (1.1%) and 44 Class 2 cases (25.9%) (log-rank test, P<10(-14)). At three years follow-up, the net reclassification improvement of GEP over TNM classification was 0.43 (p=0.001) and 0.38 (p=0.004) over chromosome 3 status. The GEP provided a highly significant improvement in prognostic accuracy over clinical TNM classification and chromosome 3 status. The impact of the test results on health outcomes were not identified in the study.

Walter (2016) evaluated two cohorts of patients at two clinical centers who underwent resection for uveal melanoma.[40] This study had similar methodology to Onken (2012) study described above. The primary cohort included 339 patients, of which 132 patients were also included in the Onken study, along with a validation cohort of 241 patients, of which 132 were also included in the Onken study, the latter group of which was used to test a prediction model using the GEP plus pretreatment largest basal diameter. Cox proportional hazards analysis was used in the primary cohort to examine GEP classification and other clinicopathologic factors (tumor diameter, tumor thickness, age, sex, ciliary body involvement, pathologic class). GEP Class 2 was the strongest predictor of metastases and mortality. Tumor diameter was also an independent predictor of outcomes, using a diameter of 12 mm as the cutoff value. In the validation cohort, GEP results were Class 1 (61.4%) in 148 patients and Class 2 (38.6%) in 93 patients.

Decatur (2016) published a smaller, retrospective study of 81 patients who had tumor samples available from resections occurring between 1998 and 2014.[41] GEP was Class 1 in 35 (43%) patients, Class 2 in 42 (52%) patients, and unknown in four (5%) patients. GEP Class 2 was strongly associated with BAP1 variants (r=0.70; p<0.001). On Cox proportional hazards analysis, GEP Class 2 was the strongest predictor of metastases and melanoma mortality.

Corrêa (2016) performed a single-institution prospective intervention case series to compare the prognostic value of the 15-gene GEP test with other conventional prognostic factors for metastasis and metastatic death, including 299 patients with posterior uveal melanoma evaluated by fine-needle aspiration biopsy at the time of or shortly prior to initial treatment.[42] The cohort in this study had a substantial proportion of patients with smaller tumors compared to previous studies, and this was reflected in the higher proportion of Class 1 to Class 2 cases in this cohort; 211 (70.6%) Class 1 patients and 88 (29.4%) Class 2 patients. Stepwise multivariant analysis determined that although GEP class was the strongest prognostic factor for metastatic death in this series; that tumor large basal diameter was also a significant prognostic indicator of metastatic death. Kaplan-Meier survival curves demonstrated lower survival in GEP Class 2 patients compared with Class 1 patients, but survival and metastasis rates by class were not reported.

Field (2016) published a follow-up study of the Onken (2010) validation cohort, looking at additional biomarkers to complement the DecisionDx-UM GEP test results in 389 consecutive patients.[43] This study analyzed 64 tumor samples previously determined as Class 1 in an
effort to find independent markers of metastasis in these samples. The investigators reported that Class 2 GEP was associated with significantly greater metastatic risk than Class 1 GEP, with metastatic disease being detected in 12/216 (6%) Class 1 cases versus 63/173 (36%) Class 2 cases (p<0.0001).

Table 3. Studies of Clinical Validity

<table>
<thead>
<tr>
<th>Study</th>
<th>Patient Populations</th>
<th>Rates of Metastases</th>
<th>Melanoma Mortality Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>GEP Class 1</td>
<td>GEP Class 2</td>
</tr>
<tr>
<td>Onken (2012)[39]</td>
<td>459 pts with UM from 12 clinical centers</td>
<td>1.1%</td>
<td>25.9%</td>
</tr>
<tr>
<td>Walter (2016)[40]</td>
<td>Primary cohort: 339 pts from one clinical center with UM arising in ciliary body or choroid</td>
<td>5.8%</td>
<td>39.6%</td>
</tr>
<tr>
<td></td>
<td>Validation cohort: 241 pts from one (different) clinical center with UM arising in ciliary body or choroid</td>
<td>2.7%</td>
<td>31.2%</td>
</tr>
<tr>
<td>Decatur (2016)[41]</td>
<td>81 pts from a single center with available tumor samples of UM arising in ciliary body or choroid</td>
<td>9.4</td>
<td>(3.1 to 28.5)</td>
</tr>
<tr>
<td>Field[43] (2016)</td>
<td>389 pts from two clinical centers with UM arising in ciliary body or choroid</td>
<td>6%</td>
<td>36%</td>
</tr>
</tbody>
</table>

GEP: gene expression profile; NR: not reported; pts: patients; UM: uveal melanoma

Clinical Utility

To date, there are no published studies that address the specificity, sensitivity, or positive- and negative-predictive values, and no studies that compare patient health outcomes as a result of patient management with versus without this testing. However, a chain of evidence based on the clinical validity of the test can be developed.

Plasseraud (2016) reported metastasis surveillance practices and patient outcomes using data from a prospective observational registry study of DecisionDx-UM conducted at four centers, which included 70 patients at the time of reporting.[44] Surveillance regimens were documented by participating physicians as part of registry data entry. “High-intensity” surveillance was defined as imaging and/or liver function testing (LFTs) every three to six months and “low-intensity” surveillance was defined as annual imaging and/or LFTs. The method for following patients for clinical outcomes was not specified. Of the 70 enrolled patients, 37 (53%) were Class 1. Over a median follow up of 2.38 years, more Class 2 patients (36%) than Class 1 patients (5%; p=0.002) experienced a metastasis. The three-year metastasis-free survival (MFS) rate was lower for Class 2 patients (63%; 95% CI, 43% to 83%) than Class 1 patients (100%; p=0.003). Most Class 1 patients (n=30) had low-intensity surveillance and all (n=33) Class 2 patients had high-intensity surveillance. Strengths of this study included a relatively large population given the rarity of the condition, and an association between management strategies and clinical outcomes. However, it is not clear which outcome measures were prespecified or how data was collected, making the risk of bias high.

Aaberg (2014) reported on changes in management associated with GEP risk classification. They analyzed Medicare claims data submitted to Castle BioSciences by 37 ocular oncologists in the United States. Data were abstracted from charts on demographics, tumor pathology and diagnosis, and clinical surveillance patterns. High-intensity surveillance was defined as a frequency of every three to six months and low-intensity surveillance was a frequency of every
6 to 12 months. Of 195 patients with GEP test results, 88 (45.1%) patients had evaluable tests and adequate information on follow-up surveillance, 36 (18.5%) had evaluable tests and adequate information on referrals, and 8 (4.1%) had evaluable tests and adequate information on adjunctive treatment recommendations. Of the 191 evaluable GEP tests, 110 (58%) were Class 1 and 81 (42%) were Class 2. For patients with surveillance data available (n=88), all patients in GEP Class 1 had low-intensity surveillance and all patients in GEP Class 2 had high-intensity surveillance (p<0.001 vs. Class 1).

PRACTICE GUIDELINE SUMMARY

There are no evidence-based clinical practice guidelines which specifically recommend the use of gene expression assays, specifically the DecisionDx assays, to guide the clinical management of patients with malignant tumors.

NATIONAL COMPREHENSIVE CANCER NETWORK

Cutaneous Melanoma

The National Comprehensive Cancer Network guidelines (v.3.2020) for cutaneous melanoma state the following regarding diagnostic testing for indeterminate melanocytic neoplasms following histopathology:[45] "Melanocytic neoplasms of uncertain biologic potential present a unique challenge to pathologists and treating clinicians. Ancillary methods to aid in benign versus malignant differentiation include molecular cytogenetics (eg, comparative genomic hybridization [CGH]), fluorescence in situ hybridization [FISH]), gene expression profiling (GEP), next generation sequencing (NGS), and immunohistochemistry (IHC), among others. While limited report on the intermediate category of melanocytic neoplasia show evolutionary pathogenic genetic alteration during melanoma progression, there are insufficient data from histologically ambiguous melanocytic neoplasms." The guidelines state the following regarding prognostic testing:

Commercially available GEP tests are marketed as being able to classify cutaneous melanoma into separate categories based on risk of metastasis. However, it remains unclear whether these tests provide clinically actionable prognostic information when used in addition to or in comparison with known clinicopathologic factors or multivariable nomograms that incorporate patient sex, age, tumor location and thickness, ulceration, mitotic rate, lymphovascular invasion, microsatellites, and SLNB status. Furthermore, the impact of these tests on treatment outcomes or follow-up schedules have not been established.

Uveal Melanoma

The National Comprehensive Cancer Network (NCCN) guidelines for uveal melanoma (v.1.2019)[46] state that biopsy specimens “should be sent for histology, chromosome analysis, and/or gene expression profiling.” The guidelines include DecisionDx-UM classes as one of the factors used to risk-stratify patients for systemic imaging.

AMERICAN ACADEMY OF DERMATOLOGY

The American Academy of Dermatology (2019) published guidelines of care for the management of primary cutaneous melanoma.[47] The guidelines state the following regarding GEP tests:

Regarding diagnostic GEP tests:
"Diagnostic molecular techniques are still largely investigative and may be appropriate as ancillary tests in equivocal melanocytic neoplasms, but they are not recommended for routine diagnostic use in CM. These include comparative genomic hybridization, fluorescence in situ hybridization, gene expression profiling (GEP), and (potentially) next generation sequencing."

"Ancillary diagnostic molecular techniques (eg, CGH, FISH, GEP) may be used for equivocal melanocytic neoplasms."

Regarding prognostic GEP tests:

"...there is also insufficient evidence of benefit to recommend routine use of currently available prognostic molecular tests, including GEP, to provide more accurate prognosis beyond currently known clinicopathologic factors" (Strength of evidence: C, Level of evidence II/III)

"Going forward, GEP assays should be tested against all known histopathologic prognostic factors and contemporary eighth edition of AJCC CM staging to assess their additive value in prognostication."

"Routine molecular testing, including GEP, for prognostication is discouraged until better use criteria are defined. The application of molecular information for clinical management (eg, sentinel lymph node eligibility, follow-up, and/or therapeutic choice) is not recommended outside of a clinical study or trial."

**SUMMARY**

There is enough research to show that the DecisionDX-UM™ genetic test can identify certain patients with uveal melanoma that are at higher risk for their cancer to spread. This information can be used to help determine how often patients should be checked for metastatic disease. Therefore, the DecisionDX-UM™ genetic test may be considered medically necessary for patients with primary, localized uveal melanoma.

There is not enough research to show that the DecisionDX-UM™ genetic test can be useful to measure risk in people with other types of disease, including people with uveal cancer that has spread from another site in the body. Therefore, the DecisionDX-UM™ genetic test is considered investigational in people who do not meet the policy criteria.

There is not enough research to show that any other gene expression tests can help to guide patient management and improve health outcomes for people with cutaneous melanoma or pigmented lesions suspected of being melanoma. Therefore, gene expression assays, including but not limited to DecisionDX-Melanoma™, Pigmented Lesion Assay, and myPath Melanoma™, are considered investigational in patients with cutaneous melanoma or pigmented lesions.

**REFERENCES**


**CODES**

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>0081U</td>
<td>Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping genes), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis (Deleted 1/1/2020)</td>
</tr>
<tr>
<td></td>
<td>0089U</td>
<td>Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)</td>
</tr>
<tr>
<td></td>
<td>0090U</td>
<td>Oncology (cutaneous melanoma) mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin embedded tissue, algorithm reported as a categorical result (ie, benign, indeterminate, or malignant)</td>
</tr>
<tr>
<td></td>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
<tr>
<td></td>
<td>81552</td>
<td>Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis</td>
</tr>
<tr>
<td></td>
<td>81599</td>
<td>Unlisted multianalyte assay with algorithmic analysis</td>
</tr>
<tr>
<td></td>
<td>84999</td>
<td>Unlisted chemistry procedure</td>
</tr>
<tr>
<td></td>
<td>88299</td>
<td>Unlisted cytogenetic study</td>
</tr>
</tbody>
</table>

**Date of Origin:** April 2013